In a significant announcement, President Trump is set to reveal a new drug pricing deal with AstraZeneca, following a similar agreement with Pfizer. This move aims to lower U.S. drug prices and pressure major drugmakers to bring manufacturing back to America. Will it lead to real savings for taxpayers?
In a bold move to reduce U.S. prescription drug prices, AstraZeneca and Pfizer have struck deals with the White House, promising significant discounts for patients. This comes amid rising pressure from President Trump on drugmakers to lower costs or face hefty tariffs. Will these changes truly benefit American patients?
In a bold move, President Trump calls for pharmaceutical companies to justify the success of their Covid drugs amid a leadership crisis at the CDC. As the FDA tightens vaccine eligibility, tensions rise over vaccine efficacy and public health transparency.
In a surprising turn, Indian drugmakers' shares jumped 5% following the U.S. exempting pharmaceuticals from new tariffs. This decision could significantly boost India's pharma exports, which reached $9 billion last year.
As President Trump prepares to unveil a major tariff plan, pharmaceutical companies are lobbying for a gradual implementation to mitigate the impact on drug prices and supply. With potential tariffs looming, how will the industry adapt?
